Product Information
BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE is a generic product labeled by Endo USA Inc., priced at $2.3908 per EA under NDC 49884015154. Its NADAC has been published 128 times since Jan 17, 2024.
BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE
Bismuth Subcitrate Potassium, Metronidazole and Tetracycline HydrochlorideStrength
140; 125; 125 mg/1; mg/1; mg/1
Manufacturer
Endo USA Inc.NDC
49884015154
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA205770On Market Since
3/7/2023
Pharmacological Classes
Price Statistics
The NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has been published 128 times since Jan 17, 2024, and over the history we have for it it has declined 53.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.3908 per EA |
|---|---|
| All-time high | $5.1282 (Feb 14, 2024) |
| All-time low | $2.3908 (Jun 17, 2026) |
| 52-week high | $4.0377 |
| 52-week low | $2.3908 |
| Median price | $3.6565 |
| Average price | $3.6568 |
| Largest weekly change | -22.6% (Jul 17, 2024) |
| Weeks tracked | 128 |
| Tracking since | Jan 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE, manufactured by Endo USA Inc., is $2.3908 per EA (NDC 49884015154), effective Jun 24, 2026.
How has the price of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has declined 53.4%. It has been tracked across 128 weekly CMS publications since Jan 17, 2024.
What are the highest and lowest recorded NADAC prices for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
Since Jan 17, 2024, the NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has ranged from a low of $2.3908 (Jun 17, 2026) to a high of $5.1282 (Feb 14, 2024), with a median of $3.6565 per EA.
Are there cheaper alternatives to BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE, so no direct lower-cost alternative is listed.
Who manufactures BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE (NDC 49884015154) is labeled by Endo USA Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification